Takeda intends to rapidly initiate the first global phase 3 trials of tak-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

Osaka, japan & cambridge, mass.--(business wire)--takeda intends to rapidly initiate the first global phase 3 trials of tak-861, an oral orexin agonist, in narcolepsy type 1 in 2024.
TAK Ratings Summary
TAK Quant Ranking